Enanta Pharmaceuticals (ENTA) - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29251M1062
Enanta Pharmaceuticals, Inc. is a biotechnology company that focuses on discovering and developing small molecule drugs to combat viral infections and liver diseases. They have a diverse product pipeline that includes EDP-514, currently in phase 1b clinical development for the treatment of chronic hepatitis B virus (HBV) infections.
In addition to EDP-514, Enanta Pharmaceuticals also has EDP-938 and EDP-323 in phase II clinical development to address respiratory syncytial virus, as well as EDP-235 for human coronaviruses. They are also known for Glecaprevir, a drug already on the market for treating chronic hepatitis C virus (HCV) infections.
The company's strategic partnerships are crucial to their success. Enanta Pharmaceuticals collaborates with Abbott Laboratories to develop, manufacture, and market HCV NS3 and NS3/4A protease inhibitor compounds such as paritaprevir and glecaprevir.
Established in 1995 and located in Watertown, Massachusetts, Enanta Pharmaceuticals continues to strive towards innovative solutions for pressing healthcare challenges. For more information, visit their official website: https://www.enanta.com.
Drawdown (Underwater) Chart
ENTA Stock Overview
Market Cap in USD | 294m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2013-03-21 |
ENTA Stock Ratings
Growth 5y | -5.15 |
Fundamental | -85.5 |
Dividend | - |
Rel. Performance vs Sector | -8.81 |
Analysts | 3.63/5 |
Fair Price Momentum | 12.13 USD |
Fair Price DCF | - |
ENTA Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
ENTA Growth Ratios
Growth 12m | -51.87% |
Growth Correlation 12m | -28% |
Growth Correlation 3m | 14% |
CAGR 5y | -31.39% |
Sharpe Ratio 12m | -0.93 |
Alpha vs SP500 12m | -75.08 |
Beta vs SP500 5y weekly | 0.82 |
ValueRay RSI | 47.33 |
Volatility GJR Garch 1y | 60.42% |
Price / SMA 50 | -13.9% |
Price / SMA 200 | 0.95% |
Current Volume | 160.5k |
Average Volume 20d | 143.6k |
External Links for ENTA Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of May 09, 2024, the stock is trading at USD 12.76 with a total of 160,469 shares traded.
Over the past week, the price has changed by -5.90%, over one month by -22.00%, over three months by +3.24% and over the past year by -62.83%.
According to ValueRays Forecast Model, ENTA Enanta Pharmaceuticals will be worth about 13.5 in May 2025. The stock is currently trading at 12.76. This means that the stock has a potential upside of +5.64%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 22.3 | 74.7 |
Analysts Target Price | 27.9 | 119 |
ValueRay Target Price | 13.5 | 5.64 |